Status:
COMPLETED
Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects
Lead Sponsor:
Yale University
Collaborating Sponsors:
Organon
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary objective of this study is to investigate the effect of Org 25935 on ketamine-induced impairments in immediate rec...
Eligibility Criteria
Inclusion
- Male, 18 - 55 years
Exclusion
- History of sensitivity/idiosyncrasy to the drugs used in the study or chemically related compounds or excipients which may be employed in the study or to any other unknown drug used in the past.
Key Trial Info
Start Date :
January 22 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 9 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00700076
Start Date
January 22 2008
End Date
March 9 2009
Last Update
March 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut, United States, 06516